IGF-1 DES

Using IGF-binding proteins isolated from bovine kidney (MDBK) cells and human amniotic fluid, the authors showed that IGFBPs markedly suppress the biological activity of intact IGF-1 and IGF-2 in chick embryo fibroblast and L6 myoblast assays by sequestering the ligands away from cell-surface receptors. In contrast, des-(1-3)-IGF-1 activity was not inhibited by the same binding proteins, which do not bind the truncated analogue. The data establish that the enhanced potency of des-(1-3)-IGF-1 is a direct consequence of its failure to be captured by purified or cell-secreted IGFBPs rather than any change in receptor affinity.

IGF-1 normally gets grabbed and held back by carrier proteins that limit how much reaches cells. This lab study found that these carrier proteins do not latch onto the truncated des(1-3) version, so it stays free and active. That escape from the carrier proteins is why des(1-3)IGF-1 works more strongly on cultured muscle and connective-tissue cells.

This review characterizes des(1-3)IGF-I, a naturally occurring analogue of IGF-I lacking the N-terminal Gly-Pro-Glu tripeptide, isolated from bovine colostrum, human brain and porcine uterus and likely arising from post-translational cleavage. Removal of the glutamate at position 3 abolishes high-affinity IGFBP binding while preserving type-1 IGF receptor binding, making the peptide roughly 10-fold more potent than intact IGF-I at stimulating cell hypertrophy and proliferation in culture. The authors note retained enhanced potency in animal models, with pronounced anabolic effects on gut tissue, but emphasize that clinical applications remained unevaluated.

This overview explains what des(1-3)IGF-1 is: a shortened natural form of IGF-1 missing three amino acids at one end. Losing those pieces means the carrier proteins can no longer hold it back, so it is about ten times stronger than regular IGF-1 at making cells grow and divide in the lab. The authors point to possible uses for muscle wasting or gut disease but stress these had not been tested in people.

In HT29-D4 human colon-carcinoma cells, endogenously produced IGF-II is functionally masked by cell-secreted IGFBPs, so the authors used des-(1-3)-IGF-I, which evades IGFBP sequestration, to probe type-1 IGF receptor signaling. Nanomolar des-(1-3)-IGF-I induced markers of enterocyte-like differentiation, including substantial carcinoembryonic antigen release and formation of well-organized microvilli, while modestly inhibiting proliferation. The results indicate that type-1 IGF receptor activation drives differentiation in these cells and that the tumor phenotype persists because the cells cannot effectively use their own IGF-II through an autocrine loop.

Colon cancer cells make their own growth factor but their carrier proteins keep it from acting. Researchers used des(1-3)IGF-1, which slips past those carrier proteins, to switch the receptor on directly. Doing so nudged the cancer cells toward a more normal, mature state and slowed their growth, showing the receptor can push these cells to differentiate.